Title : Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.

Pub. Date : 2020 Oct

PMID : 32020437






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin (active principle [AP]) that allows for IV administration. RG7388 MDM2 proto-oncogene Homo sapiens